Table 2 Clinicopathological characteristics, treatments after local recurrence and outcome of patients with local wall recurrence
Patient No | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical characteristics | ||||||||||||
Primary | ||||||||||||
Age | 51 | 45 | 40 | 37 | 39 | 37 | 48 | 41 | 46 | 40 | 47 | 45 |
Tumor size | Is | Is | Is | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
Nodal status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Stage | 0 | 0 | 0 | I A | I A | I A | I A | II A | II B | II B | II B | II B |
MRI findings | Segmental | Segmental | Segmental | Segmental | Segmental | Segmental | Segmental | Segmental | Isolated mass | Segmental | Segmental | Segmental |
Operation | NSM | TM | TM | TM | TM | TM | TM | TM | TM | TM | TM | TM |
Adjuvant therapy | – | – | – | HT | HT | – | HT | CT, HT | CT + Trastuzumab | oral CT, HT | CT, HT | CT, HT |
Opportunity to detect recurrent lesions | Nipple erosion | Palpation | Imaging inspection | Palpation | Palpation | Palpation | Palpation | Palpation | Palpation | Imaging inspection | Palpation | Palpation |
Recurrence | ||||||||||||
Local recurrence site | ||||||||||||
Needle biopsy tract | + | + | + | |||||||||
Skin just above primary lesion | + | + | ||||||||||
Subcutaneous tumor around primary lesion | + | + | + | + | + | + | + | |||||
Other | Residual nipple | |||||||||||
Other recurrent site | – | – | – | – | – | – | – | – | – | Bone, Lung | – | – |
Pathological characteristics (Primary/Recurrence) | ||||||||||||
Histology | DCIS/Paget's disease with invasion | DCIS/IDC | DCIS/IDC | Mucinous/Mucinous | IDC + ILC/IDC | IDC/lymph node metastasis | IDC/lymph node metastasis | Mucinous/Mucinous | IDC/IDC | IDC/IDC | IDC/IDC | IDC/IDC |
Hormone receptor | −/− | + / + | + / + | + / + | + / + | −/− | + / + | + / + | + / + | + / + | + / + | + / + |
HER2 | + / + | −/− | −/− | −/− | −/− | + / + | −/ + | −/− | + / + | −/− | −/− | −/− |
Ki-67 | < 15%/ > 80% | < 15%/ < 15% | < 30%/ < 15% < 15% < 15% < < 15% | < 15%/ < 15% | < 15%/ < 15% | < 80%/ < 50% | < 30%/ < 15% < 15% < 15% | < 30%/ < 15% | < 80%/ < 50% | < 15%/ < 15% | < 15%/ < 15% | > 15%/ < 50% 30,305,050% |
Subtype | HER/HER | LA/LA | LA/LA | LA/LA | LA/LA | HER/HER | LB/LH | LB/LA | HER/HER | LA/LA | LA/LA | LB/LB |
Pathological characteristics ( Before/After recurrence) | ||||||||||||
Nuclear grade* | High/3 | Low/1 | Intermediate/1 11/1 | 1/1 | 1/1 | 3/3 | 3/3 | 2/1 | 3/3 | 1/1 | 1/1 | 2/3 |
Lymphatic vessel invasion | −/ + | −/− | −/− | ± | + / + | + / + | + / + | ± | + / + | + / + | + / + | + / + |
Vertical margin (at the time of reconstruction) | Not evaluated | < 2 mm: DCIS | < 2 mm: DCIS | < 2 mm: Invasive | < 2 mm: DCIS | + : DCIS | < 2 mm: DCIS | < 2 mm: DCIS | < 2 mm: Invasive | Not evaluated | < 2 mm: Invasive | – |
Tissues from recurrence site | Residual nipple lactiferous duct | Residual mammary tissue | Residual mammary tissue | Subcutaneous fat | Skin ~ subcutaneous fat | Lymph node | Lymph node | Subcutaneous fat | Skin | Skin ~ subcutaneous fat | Skin ~ subcutaneous fat | Skin ~ subcutaneous fat |
Treatment after recurrence | ||||||||||||
Operation | + | + | + | + | + | + | + | + | + | + | + | + |
Radiation | – | + | + | + | – | + | + | + | + | – | + | + |
Pharmacological treatment | HT, CT + Trastuzumab | HT | HT | HT | HT | CT + Trastuzumab | HT | HT | T-DM1 | HT | HT | CT, HT |
Outcome | ||||||||||||
Local recurrence free survival (M) | 155 | 42 | 122 | 19 | 31 | 12 | 39 | 12 | 9 | 24 | 19 | 71 |
Overall survival (M) | 184 | 61 | 127 | 97 | 75 | 57 | 57 | 57 | 61 | 71 | 55 | 86 |
Survival | + | + | + | + | + | + | + | + | + | + | + | + |